Last reviewed · How we verify

Anti-inflammatory drugs

Genentech, Inc. · Phase 3 active Small molecule

Anti-inflammatory drugs reduce inflammation by inhibiting inflammatory pathways and mediators in the body.

At a glance

Generic nameAnti-inflammatory drugs
SponsorGenentech, Inc.
ModalitySmall molecule
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

Anti-inflammatory drugs work through various mechanisms depending on the specific agent, commonly by inhibiting cyclooxygenase (COX) enzymes, suppressing cytokine production, or modulating immune cell activity. Genentech's anti-inflammatory candidates in Phase 3 typically employ biologic mechanisms such as monoclonal antibodies targeting specific inflammatory cytokines or their receptors. These approaches aim to reduce excessive immune activation while preserving beneficial immune function.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: